Since 2007, Oded has served as CEO of NeuroDerm (NASDAQ:NDRM), based in Rehovot (Israel). Neuroderm develops next-generation treatments for CNS disorders, with a focus on Parkinson’s disease. NeuroDerm’s lead product, ND0612, could gain FDA approval in 2019. Mitsubishi Tanabe’s offer was approved by NeuroDerm’s shareholders on September 12, 2017.
Source: http://www.fiercebiotech.com/biotech/mitsubishi-tanabe-buys-up-neuroderm-1-1b-deal
